Effective accumulation of poly(vinylpyrrolidone-co-vinyl laurate) into the spleen

Journal of Biomedical Materials Research - Part A

Volumn 70, Issue 2, 2004, Pages 219-223

  Yoshioka, Yasuo ^a   Tsutsumi, Yasuo ^a   Mukai, Yohei ^a   Shibata, Hiroko ^a   Okamoto, Takayuki ^a   Kaneda, Yoshihisa ^a   Tsunoda, Shin Ichi ^a   Kamada, Haruhiko ^a   Koizumi, Keiichi ^a   Yamamoto, Yoko ^a   Mu, Yu ^a   Kodaira, Hiroshi ^a   Sato Kamada, Keiko ^a   Nakagawa, Shinsaku ^a   Mayumi, Tadanori ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Drug delivery system; Hydrophobic; Polymeric carrier; Polyvinylpyrrolidone; Targeting

Indexed keywords

BIOPOLYMERS; BLOOD; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS;

CYTOTOXICITY; POLYMERIC DRUG DELIVERY SYSTEMS;

BIOMATERIALS;

POLY(VINYLPYRROLIDONE CO VINYL LAURATE); POVIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; ENDOTHELIUM CELL; HYDROPHOBICITY; IN VITRO STUDY; LIVER; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; SPLEEN; TISSUE SPECIFICITY;

EID: 3342875557     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.30059     Document Type: Article

References (16)

1. Furman WL, Strother D, McClain K, Bell B, Leventhal B, Pratt CB. Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 1993;11:2205-2210.
2. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241-247.
3. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;32: 647-653.
4. Barnard DL. Pegasys (Hoffmann-La Roche). Curr Opin Investig Drugs 2001;2:1530-1538.
5. Skillings J, Wierzbicki R, Eisenhauer E, Venner P, Letendre F, Stewart D, Weinerman B. A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Immunother 1992;11:67-70.
6. Sparano JA. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Semin Oncol 1999;26:14-19.
7. Kaneda Y, Yamamoto Y, Kamada H, Tsunoda S, Tsutsumi Y, Hirano T, Mayumi T. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice. Cancer Res 1998;58: 290-295.
8. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000;97:8548-8553.
9. Kamada H, Tsutsumi Y, Yamamoto Y, Kihira T, Kaneda Y, Mu Y, Kodaira H, Tsunoda SI, Nakagawa S, Mayumi T. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice. Cancer Res 2000;60: 6416-6420.
10. Kamada H, Tsutsumi Y, Sato-Kamada K, Yamamoto Y, Yoshioka Y, Okamoto T, Nakagawa S, Nagata S, Mayumi T. Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application as renal targeting carrier. Nat Biotechnol 2003;21:399-404.
11. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, Mukai Y, Shimizu T, Nakagawa S, Nagata S, Mayumi T. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 2003;21:546-552.
12. Kaneda Y, Tsutsumi Y, Yoshioka Y, Kamada H, Yamamoto Y, Kodaira H, Tsunoda S, Okamoto T, Mukai Y, Shibata H, Nakagawa S, Mayumi T. The use of PVP as a polymeric carrier to improve the plasma half-life of drugs. Biomaterials 2004;25: 3259-3266.
13. Tsunoda S, Kamada H, Yamamoto Y, Ishikawa T, Matsui J, Koizumi K, Kaneda Y, Tsutsumi Y, Ohsugi Y, Hirano T, Mayumi T. Molecular design of polyvinylpyrrolidone-conjugated interleukin-6 for enhancement of in vivo thrombopoietic activity in mice. J Control Release 2000;68:335-341.
14. Kodaira H, Tsutsumi Y, Yoshioka Y, Kamada H, Kaneda Y, Yamamoto Y, Tsunoda S, Okamoto T, Mukai Y, Shibata H, Nakagawa S, Mayumi T. The targeting of anionized polyvinylpyrrolidone to the renal system. Biomaterials 2004;25:4309-4315.
15. Yamamoto Y, Yasugi K, Harada A, Nagasaki Y, Kataoka K. Temperature-related change in the properties relevant to drug delivery of poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles in aqueous milieu. J Control Release 2002;82: 359-371.
16. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113:383-389.